Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study

被引:1
作者
Liu, Dian [1 ,2 ]
Quan, Hu [2 ,3 ]
Ma, Min [4 ]
Zhou, Huijun [5 ]
Yang, Xiaolin [5 ]
Wu, Zhengchun [2 ,3 ]
Luo, Jia [2 ,3 ]
Xiao, Hua [2 ,3 ,6 ]
Xiao, Yanping [7 ]
机构
[1] Cent South Univ, Hunan Canc Hosp, Dept Lamphoma & Abdominal Radiotherapy, Changsha 410013, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha 410013, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Hepatobiliary & Intestinal Surg, Changsha 410013, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Gastrointestinal Surg, Changsha 410013, Peoples R China
[5] Cent South Univ, Hunan Canc Hosp, Dept Gastroenterol & Urol, Changsha 410013, Peoples R China
[6] Cent South Univ, Affiliated Canc Hosp, Hanun Canc Hosp, Xiangya Sch Med,Dept Gastroduodenal & Pancreat Sur, Changsha 410013, Peoples R China
[7] Changsha Hlth Vocat Coll, Dept Sci Res, Changsha 410605, Peoples R China
关键词
Gastric cancer; Adjuvant chemotherapy; Survival; Nomogram; Validation; INDEPENDENT RISK-FACTOR; OPEN-LABEL; S-1; SURGERY; ADENOCARCINOMA; CLASSIFICATION; CAPECITABINE; CONTINUATION; OXALIPLATIN;
D O I
10.1186/s12885-024-12103-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTo establish a nomogram to predict the probability of survival of patients with stage II/III gastric cancer (GC) who received incomplete peri-operative adjuvant chemotherapy (PAC). MethodsThe medical records of stage II/III GC patients who received curative resection and 1 to 5 cycles of PAC from two tertiary hospitals were retrospectively reviewed. Patients were randomly classified into either a training group or validation group at a ratio of 7:3. The nomogram was constructed based on various prognostic factors using Cox regression analysis in the training cohort, and was validated by the validation group. Concordance index and calibration curves were used to evaluate the discrimination and calibration of the nomogram. Additionally, decision curve analysis (DCA) was used to compare the net clinical benefits of the nomogram and eighth version of TNM staging system. ResultsA total of 1,070 consecutive patients were included and 749 patients were enrolled into the training group. Lower body mass index (< 18.5 kg/m(2)), total gastrectomy, stage III disease and fewer cycles of PAC were identified to be independent predictors for poorer survival. The area under the curve (AUC) values of receiver operating characteristics (ROC) curve predicting 5-year survival probabilities and C-index were 0.768 and 0.742, 0.700 (95%CI: 0.674-0.726) and 0.689 (95%CI: 0.646-0.732) in the training and validation groups, respectively. The calibration curves in the validation cohort showed good agreement between the prediction and observation of 1-, 3- and 5-year survival probabilities. Furthermore, DCA showed that our model has a better net benefit than that of TNM staging system. ConclusionsThe findings emphasize the value of completing PAC. The nomogram which was established to predict survival probability in patients with stage II/III GC receiving radical gastrectomy and incomplete PAC had good accuracy and was verified through both internal and external validation.
引用
收藏
页数:12
相关论文
共 30 条
  • [1] Gastric Cancer, Version 3.2016
    Ajani, Jaffer A.
    D'Amico, Thomas A.
    Almhanna, Khaldoun
    Bentrem, David J.
    Chao, Joseph
    Das, Prajnan
    Denlinger, Crystal S.
    Fanta, Paul
    Farjah, Farhood
    Fuchs, Charles S.
    Gerdes, Hans
    Gibson, Michael
    Glasgow, Robert E.
    Hayman, James A.
    Hochwald, Steven
    Hofstetter, Wayne L.
    Ilson, David H.
    Jaroszewski, Dawn
    Johung, Kimberly L.
    Keswani, Rajesh N.
    Kleinberg, Lawrence R.
    Korn, W. Michael
    Leong, Stephen
    Linn, Catherine
    Lockhart, A. Craig
    Ly, Quan P.
    Mulcahy, Mary F.
    Orringer, Mark B.
    Perry, Kyle A.
    Poultsides, George A.
    Scott, Walter J.
    Strong, Vivian E.
    Washington, Mary Kay
    Weksler, Benny
    Willett, Christopher G.
    Wright, Cameron D.
    Zelman, Debra
    McMillian, Nicole
    Sundar, Hema
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10): : 1286 - 1312
  • [2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [3] Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
    Aoyama, Toru
    Kawabe, Taiichi
    Fujikawa, Hirohito
    Hayashi, Tsutomu
    Yamada, Takanobu
    Tsuchida, Kazuhito
    Yukawa, Norio
    Oshima, Takashi
    Rino, Yasushi
    Masuda, Munetaka
    Ogata, Takashi
    Cho, Haruhiko
    Yoshikawa, Takaki
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) : 2560 - 2566
  • [4] Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
    Aoyama, Toru
    Yoshikawa, Takaki
    Shirai, Junya
    Hayashi, Tsutomu
    Yamada, Takanobu
    Tsuchida, Kazuhito
    Hasegawa, Shinichi
    Cho, Haruhiko
    Yukawa, Norio
    Oshima, Takashi
    Rino, Yasushi
    Masuda, Munetaka
    Tsuburaya, Akira
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) : 2000 - 2006
  • [5] Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
    Cats, Annemieke
    Jansen, Edwin P. M.
    van Grieken, Nicole C. T.
    Sikorska, Karolina
    Lind, Pehr
    Nordsmark, Marianne
    Kranenbarg, Elma Meershoek-Klein
    Boot, Henk
    Trip, Anouk K.
    Swellengrebel, H. A. Maurits
    van Laarhoven, Hanneke W. M.
    Putter, Hein
    van Sandick, Johanna W.
    Henegouwen, Mark I. van Berge
    Hartgrink, Henk H.
    van Tinteren, Harm
    van de Velde, Cornelis J. H.
    Verheij, Marcel
    [J]. LANCET ONCOLOGY, 2018, 19 (05) : 616 - 628
  • [6] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, David
    Allum, William H.
    Stenning, Sally P.
    Thompson, Jeremy N.
    Van de Velde, Cornelis J. H.
    Nicolson, Marianne
    Scarffe, J. Howard
    Lofts, Fiona J.
    Falk, Stephen J.
    Iveson, Timothy J.
    Smith, David B.
    Langley, Ruth E.
    Verma, Monica
    Weeden, Simon
    Chua, Yu Jo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20
  • [7] Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
    Dindo, D
    Demartines, N
    Clavien, PA
    [J]. ANNALS OF SURGERY, 2004, 240 (02) : 205 - 213
  • [8] Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer
    Hosoda, Kei
    Ushiku, Hideki
    Katada, Chikatoshi
    Ishido, Kenji
    Niihara, Masahiro
    Sakuraya, Mikiko
    Araki, Ippeita
    Washio, Marie
    Harada, Hiroki
    Yamashita, Keishi
    Hiki, Naoki
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2021, 406 (04) : 1045 - 1055
  • [9] Jang SH, 2018, J GASTRIC CANCER, V18, P48
  • [10] Japanese gastric cancer treatment guidelines 2018 (5th edition)
    Japanese Gastric Cancer Association
    [J]. GASTRIC CANCER, 2021, 24 (01) : 1 - 21